Abstract: A series of twenty arylpiperazine derivatives of 1,7,8,9-tetrachloro-10,10-dimethoxy-4-azatricyclo[5.2.1.0 2,6 ]dec-8-ene-3,5-dione have been prepared. These derivatives were tested in vitro with the aim of identifying novel lead compounds active against emergent and re-emergent human and cattle infectious diseases (AIDS, hepatitis B and C, tuberculosis, bovine viral diarrhea). In particular, these compounds were evaluated in vitro against representatives of different virus classes, such as a HIV-1 (Retrovirus), a HBV (Hepadnavirus) and the single-stranded RNA + viruses Yellow fever virus (YFV) and Bovine viral diarrhea virus (BVDV), both belonging to the Flaviridae. Compounds 2c, 2g and 3d showed a modest activity against CVB-2. The molecular structures of the starting imide 1 and one of propyl-piperazine derivatives, 3b, have been determined by an X-ray crystallography study.
Introduction
It is widely recognized that the utility of most antiviral agent is limited by the inherent toxicity of the compounds and the appearance of drug resistant virus following their continued use. As such, there is great interest in the identification of novel antiviral agents and lead compounds from which new antivirals might be synthesized. Viruses belonging to the Flaviviridae family have a single-stranded, positive-sense RNA genome (ssRNA + ) [1] . Members of the Flaviviridae family can be classified into three genera: Hepaciviruses, Flaviviruses and Pestiviruses [2] [3] [4] .
Some members of the Flaviviridae family can infect only animals, causing severe diseases usually followed by death [eg. bovine viral diarrhea virus (BVDV), classical swine fever virus (CSFV) and border disease virus (BDV)] [5] . In humans infections with Flaviviridae viruses may cause fulminant, hemorrhagic diseases [Yellow fever virus (YFV), dengue fever virus (DENV) and Omsk hemorrhagic fever virus (OHFV)], viral encephalitis [Japanese encephalitis virus (JEV), tick-borne encephalitis virus (TBEV), West Nile virus (WNV), St. Luis encephatitis virus (SLEV)] or hepatitis, formerly referred to as non-A, non-B hepatitis [hepatitis C virus (HCV)] [4] [5] [6] . Globally HCV is a major cause of human hepatitis [7, 8] . Most infections become persistent, and about 60% of cases progress toward chronic liver disease, which in turn, can lead to development of cirrhosis, hepatocellular carcinoma, and liver failure [9, 10] . There is a vaccine against the various Flaviviridae members with the exception of YFV; new therapies and preventative agents are strongly needed.
Other important ssRNA + viruses are those belonging to the Picornaviridae family. This family includes nine genera, some of which comprise major human pathogens, namely, Enterovirus (including Poliovirus, Coxsackievirus, Echovirus), Rhinovirus (approximately 105 serotypes), and Hepatovirus [Hepatitis A virus (HAV)]. The range of clinical syndromes associated with enteroviruses is legion and includes acute paralysis, aseptic meningitis, encephalitis, carditis, pleurodynia, conjunctivitis, hand food and mouth disease and other enanthems [11] . While many of these diseases are relatively benign, others, such as encephalitis and carditis, may be fatal. A fascinating aspect of these clinical syndromes is that different enteroviruses may be associated with the same clinical syndrome. Conversely, the same enterovirus may cause different clinical syndromes. Moreover, these associations are not always predictable: A given virus may behave differently, both clinically and epidemiologically, in different places at different times [12] . At present, no specific antiviral therapy is available for the treatment of Picornaviridae infections. Some arylpiperazine derivatives possess antienteroviral activity [13, 14] . Piperazine fragment there are in anti-HIV agents bis(heteroaryl)piperazines (BHAPs), such as delavirdine and atevirdine [15] . Another arylpiperazine, vicriviroc, is currently under II phase of clinical investigation [16] . Inspired by these reports, we have recently synthesized and tested in vitro a series of arylpiperazine derivatives of a tricyclic imide for cytotoxicity and antiviral activity against representative viruses assays. The title compounds were also tested against representatives of other virus families. AZT (3'-azidothymidine), NM 108 (2'-β-methylguanosine), NM 176 (2'-ethynyl-D-cytidine), M 5255 (mycophenolic acid) and ACG (acycloguanosine) were used as reference inhibitors of ssRNA+, ssRNA-and DNA viruses, respectively.
Scheme 1. Compound Synthesis.
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Results and Discussion
The preparation of the compounds was accomplished according to the reactions described in Scheme 1. The starting compound, 1,7,8,9- The molecular structure of starting imide 1 and one of propylpiperazine derivatives, 3b, has also been determined by an X-ray crystallography study ( Table 2 ). The configuration of the cycloalkene skeleton of the imide 1 is endo, cis (Figure 1 ). This compound crystallizes with two symmetrically independent molecules, A and B, both adopting similar orientations of the -OCH 3 groups in the solid state. The alternating molecules A and B are linked through four intermolecular N-H...O hydrogen bonds forming centrosymmetric tetramer. This type of molecular association excludes imide groups from further hydrophilic contacts.
The N-propyl-piperazine derivative 3b adopts an extended conformation. In its protonated form it exists as a cation/anion pair ( Figure 1) Limiting indices The synthesized arylpiperazine derivatives were evaluated in vitro in parallel cell-based assays for cytotoxicity and antiviral activity (Table 3 ) against viruses representative of two of the three genera of the Flaviviridae family, i.e., Flaviviruses (YFV) and Pestiviruses (BVDV). The title compounds were also tested against representatives of other virus families. Among ssRNA+ were a Retrovirus (Human Immunodeficiency Virus type 1, HIV-1), two Picornaviruses (Coxsackie Virus type B2, CVB-2, and Poliovirus type-1, Sabin strain, Sb-1); among ssRNA-were a Paramyxoviridae (a Rhabdoviridae, Vesicular Stomatitis Virus, VSV) representative. Among double-stranded RNA (dsRNA) viruses was a Reoviridae representative (Respiratory Enteric Orphan Virus type-1, Reo-1). Two representatives of DNA virus families were also included: Herpes Symplex type 1, HSV-1 (Herpesviridae) and Vaccinia Virus, VV (Poxviridae). Although compound 1 was characterized by high cytotoxicity (Table 3) , its derivatives possessed considerably low cytotoxicity. None of the compounds showed any activities against all viruses tested, with the exception of compounds 2c, 2g and 3d, that showed a modest activity against CVB-2-mediated diseases and potentiality as therapeutic targets (EC 50 range = 10-17 μM) ( Table 3) . -----2a  80  >80  >80  >80  >80  >80  2b  95  >95  >95  >95  >95  >95  2c  84  >84  >84  >84  13  >84  2d  95  >95  >95  >95  >95  >95  2e  60  >60  >60  >60  >60  >60  2g  95  >95  >95  >95  10  >95  2h  70  >70  >70  >70  >70  >70  2i  45  >45  >45  >45  >45  >45  2j  52  >52  >52  >52  >52  >52  3a  60  >60  >60  >60  >60  >60  3c  70  >70  >70  >70  >70  >70  3d  82  >82  >82  >82  17  >82  3e  75  >75  >75  >75  >75  >75  3i  34  >34  >34  >34  >34 
Experimental
General
Melting points were determined in a Kofler's apparatus and are uncorrected. ]dec-8-ene-3,5-dione (1) was synthesized as previously described [17] . ]dec-8-ene-3,5-dione (2) . A mixture of imide 1 (0.5 g, 0.00138 mol), dibromobutane (0.9 g, 0.0027 mol) and anhydrous K 2 CO 3 (0.5 g, 0.0036 mol) in acetonitrile (50 mL) was refluxed for 8 h. The inorganic precipitate was filtered off and the solvent was evaporated. For characterization data see Table 1 .
1,7,8,9-Tetrachloro-4-(3-chloro-propyl)-10,10-dimethoxy-4-aza-tricyclo[5.2.1.0 2,6 ]dec-8-ene-3,5-dione (3)
. A mixture of imide 1 (0.5 g, 0.00138 mol), 1-bromo-3-chloropropane (0.6 g, 0.00415 mol) and anhydrous K 2 CO 3 (0.5 g, 0.0036 mol) in acetonitrile (50 mL) was refluxed for 8 h. The inorganic precipitate was filtered off, the solvent was evaporated. For characterization data see Table 1 .
General procedure for the preparation of arylpiperazine derivatives 2a-2j and 3a-3j
A mixture of compound 2 (0.3 g; 0.0006 mole) or 3 (0.3 g; 0.0007 mole), an appropriate amine (0.00137 or 0.0012 mole), anhydrous K 2 CO 3 (0.3 g, 0.0022 mole) and KI (0.2 g, 0.0012 mole) was dissolved in acetonitrile (50 mL) and refluxed for 30 h. The solvent was evaporated, then the residue was purified by column chromatography (eluent: CH 2 Cl 2 -CH 3 OH, 95:5) to give compounds 2a-2j and 3a-3j, respectively.
General procedure for the preparation of hydrochloride salts of compounds 2a-2j and 3a-3j
The solid product was dissolved in methanol saturated with gaseous HCl. The hydrochloride was precipitated by addition of diethyl ether. The crude product was crystallized from methanol/ethyl ether. Characterization data is given in Table 1 .
X-Ray crystal structure analysis of 1 and 3b diethyl ether hemisolvate
Measurements were carried out at 292 K with a KM4 diffractometer using graphite monochromated CuK α radiation (λ = 1.54178 Å) and ω/2θ scan mode. Intensities were corrected for absorption. Structure was solved by the SHELXS-97 program and refined by full-matrix least-squares on F 2 using the SHELXL-97 program [18] . The non-H atoms were refined anisotropically. The H-atom positions were calculated from geometry and the 'riding' model for the C-H bonds was used in the refinement. The N-bonded H-atoms were located in the difference maps. Crystal data are listed in 
Cell-based assays
Compounds were dissolved in DMSO at 100 mM and then diluted in culture medium. fetal calf serum (FCS), 100 units/mL penicillin G and 100 µg/mL streptomycin. Cell cultures were then incubated at 37 °C in a humidified, 5% CO 2 atmosphere in the absence or presence of serial dilutions of test compounds. Cell viability was determined after 96 hrs at 37 °C by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) method [18] . 
